Cell and Gene Therapy Catapult published a blog by Ted Mason discussing how automation streamlined AAV analytical capabilities through the integration of an automated DNA impurity detection assay.
Published
Signal category
Research & Knowledge
Quote
“In this newly released blog, Ted Mason, one of our laboratory technicians, discusses how we have streamlined our AAV analytical capabilities through the integration of an automated assay for DNA impurity detection”
— Cell and Gene Therapy Catapult team
Company
Cell and Gene Therapy Catapult
Enhancing productivity and growth in the cell and gene therapy industry 🧬🩺🌍
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 323 employees
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 300 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.
Founded 2012